Zikani Therapeutics Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 20
Employees
  • Latest Deal Type
  • Series A1
  • Latest Deal Amount
  • $7.5M
Latest Deal Amount
  • Investors
  • 7

Zikani Therapeutics General Information

Description

Developer of novel antibiotic compounds created to improve the lives of patients suffering from serious infections. The company's fifth-generation macrolide antibiotics harnesses the power of synthetic chemistry and microbiology used in the treatment of serious, multi-drug resistant gram-negative infections, enabling patients to recover quickly from multiple infection conditions.

Contact Information

Website
Formerly Known As
Macrolide Pharmaceuticals
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 480 Arsenal Way
  • Suite 130
  • Watertown, MA 02472
  • United States
+1 (617) 000-0000

Zikani Therapeutics Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Zikani Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series A1) 09-Apr-2020 $7.5M 000.00 000.00 Completed Generating Revenue
4. Early Stage VC (Series A) 02-Apr-2018 0000 000.00 000.00 Completed Startup
3. Grant 26-Mar-2018 00.00 000.00 Completed Startup
2. Early Stage VC (Series A) 25-Feb-2015 $22.3M $22.3M 000.00 Completed Startup
1. Accelerator/Incubator Completed Startup
To view Zikani Therapeutics’s complete valuation and funding history, request access »

Zikani Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A1 000,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00.00 00 00 00 00 00.00
To view Zikani Therapeutics’s complete cap table history, request access »

Zikani Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel antibiotic compounds created to improve the lives of patients suffering from serious infections. The
Drug Discovery
Watertown, MA
20 As of 2020
000.00
00.00 0000-00-00
00000000000 000.00

00000000

ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
0000 000000000
Basel, Switzerland
00 As of 0000
000.00
00.00 0000-00-00
00000000000 000.00

00000 00

m dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui
0000 000000000
San Diego, CA
000.00
0000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Zikani Therapeutics Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioVersys Venture Capital-Backed Basel, Switzerland 00 000.00 00000000000 000.00
00000 000000000000 Venture Capital-Backed San Diego, CA 000.00 0000000000 000.00
00000 000000000000 Formerly VC-backed Cambridge, MA 00 00000 000000 - 000 00000
0000000 0000000000 Venture Capital-Backed Boston, MA 0 000.00 00000000000 000.00
00000000 Formerly VC-backed South San Francisco, CA 00 00000 0000000000.
You’re viewing 5 of 13 competitors. Get the full list »

Zikani Therapeutics Executive Team (13)

Name Title Board Seat Contact Info
Sumit Aggarwal Chief Executive Officer, Board Member and President
Yoshitaka Ichikawa Ph.D Vice President
Daniel Geffken Chief Financial Officer
Vijay Modur Chief Scientific & Medical Officer & Head, Research & Development
Alan Walts Ph.D Executive Chairman
You’re viewing 5 of 13 executive team members. Get the full list »

Zikani Therapeutics Board Members (17)

Name Representing Role Since
Alan Walts Ph.D Self Executive Chairman 000 0000
Andrew Myers Ph.D Zikani Therapeutics Co-Founder, Board of Scientific Advisor & Board Member 000 0000
Anja Harmeier Ph.D Roche Venture Fund Board Member 000 0000
Christopher Viehbacher Gurnet Point Capital Board Member 000 0000
Joseph Zakrzewski Self Board Member 000 0000
You’re viewing 5 of 17 board members. Get the full list »

Zikani Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zikani Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CARB-X Government 000 0000 000000 0
Advent Life Sciences Venture Capital Minority 000 0000 000000 0
Gurnet Point Capital PE/Buyout Minority 000 0000 000000 0
Novartis Venture Fund Corporate Venture Capital Minority 000 0000 000000 0
Roche Venture Fund Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »